Increased patient engagement

In the real world, increased engagement with the FreeStyle Libre Portfolio strongly relates to improved glycemic control.1,2,*

Man smiling and walking on outdoor trail while wearing FreeStyle Libre sensor
Man smiling and walking on outdoor trail while wearing FreeStyle Libre sensor
Man smiling and walking on outdoor trail while wearing FreeStyle Libre sensor

Increased engagement

On average, users of the FreeStyle Libre Portfolio scanned more often than the 6-10 glucose tests per day recommended by the ADA.3,4,*,† More frequent glucose monitoring with the FreeStyle Libre Portfolio is associated with better outcomes.5,* 

>2x

more patients reported knowing what to do after measuring glucose compared to when they used blood glucose meters6,* 

95%

reported having a better understanding of their glucose fluctuations

62%

reported that family and roommates were less worried about their diabetes when using the FreeStyle Libre portfolio

FreeStyle Libre 2 system

  • Unsurpassed 14 day accuracy7 for adults and children (age 4 and older) with diabetes

  • Optional, real-time glucose alarms§ with readings every minute7

  • Easy set up and no patient training required8

FreeStyle Libre 14 day CGM system available for prescription with sensor, reader, and smartphone app as the best CGM technology in the U.S.

Integrated system - The components of the FreeStyle Libre 2 system work together seamlessly to offer patients, caregivers, and healthcare professionals easily shared glucose data and insights‖,¶,#,**

Patients on a FreeStyle Libre app platform sharing results with their physicians use more sensors8,††

Patients using the FreeStyle Libre app platform are more adherent to the use of FreeStyle Libre 2 sensors8,††

87% of patients sharing results on a FreeStyle Libre app platform with their physicians continue using sensors after 12 months8,††

Please contact us for more information.

Medicare coverage is available for the FreeStyle Libre 2 system if the FreeStyle Libre 2 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply. Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

The FreeStyle Libre 2 system is indicated for use in people with diabetes age 4 and older.

 

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
† 2020 ADA recommendation for patients self-monitoring blood glucose (SMBG) on multiple-dose insulin or insulin pump therapy.
‡ Compared to patients using SMBG.
§ Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.
‖ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
¶ The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
# The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check http://www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. Dosing decisions should not be made based on this device. The user should follow instructions on the continuous glucose monitoring system. This device is not intended to replace self-monitoring practices as advised by a physician.
** The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
†† In comparison to patients on a FreeStyle Libre app not sharing with their physicians. Data has been extended from analysis on the FreeStyle Libre 14 day system.

References: 1. Dunn, Timothy, et al. "Evidence of a Strong Association Between Frequency of Flash Glucose Monitoring and Glucose Control Measures During Real-World Usage." E-poster presentation presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Paris, France, February 15-18, 2017. 2. Jangam, Sujit, et al. “Sustained improvement in glycemic control following flash glucose monitoring: a worldwide observational analysis.” Poster presentation presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Vienna, Austria, February 14-17, 2018. 3. American Diabetes Association. “7. Diabetes technology: Standards of Medical Care in Diabetes—2021.” Diabetes Care 44, no. Supplement 1 (2021):S85–S99. 4. Calliari, Luis Eduardo P., Marcio Krakauer, Andre Gustavo Daher Vianna, Yashesvini Ram, Douglas Eugenio Barbieri, Yongjin Xu, and Timothy C. Dunn. “Real-world flash glucose monitoring in Brazil: can sensors make a difference in diabetes management in developing countries?” Diabetology & Metabolic Syndrome 12, no. 1 (2020): 1-7. 5. Dunn, Timothy C., Yongjin Xu, Gary Hayter, and Ramzi A. Ajjan. “Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests.” Diabetes Research and Clinical Practice 137 (2018): 37-46. 6. Fokkert, Marion, Peter van Dijk, Mireille Edens, Eglantine Barents, Jeanine Mollema, Robbert Slingerland, Reinold Gans, and Henk Bilo. “Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).” BMJ Open Diabetes Research and Care 7, no. 1 (2019). https://doi.org/10.1136/bmjdrc-2019-000809. 7. FreeStyle Libre 2 User's Manual. 8. Data on file. Abbott Diabetes Care.

ADC-17129 v4.0 02/22